

Paul J Goodfellow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2519405/publications.pdf>

Version: 2024-02-01

163
papers

11,975
citations

34105

52
h-index

29157

104
g-index

164
all docs

164
docs citations

164
times ranked

16091
citing authors

#	ARTICLE	IF	CITATIONS
1	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	1.4	24
2	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	4.1	62
3	High prevalence of actionable germline variants in unselected endometrial cancer (EC) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5577-5577.	1.6	0
4	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. <i>JCO Precision Oncology</i> , 2021, 5, 779-791.	3.0	31
5	Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?. <i>Oncologist</i> , 2021, 26, 1044-1051.	3.7	7
6	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. <i>JCO Precision Oncology</i> , 2021, 5, 1588-1602.	3.0	15
7	Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. <i>Neoplasia</i> , 2020, 22, 484-496.	5.3	7
8	Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer. <i>Cancer Research</i> , 2020, 80, 857-867.	0.9	33
9	Adipokines Deregulate Cellular Communication via Epigenetic Repression of <i>Gap Junction</i> Loci in Obese Endometrial Cancer. <i>Cancer Research</i> , 2019, 79, 196-208.	0.9	16
10	GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2019, 153, 335-342.	1.4	6
11	<i>Dicer1</i> Phosphomimetic Promotes Tumor Progression and Dissemination. <i>Cancer Research</i> , 2019, 79, 2662-2668.	0.9	10
12	Mismatch repair deficiency identifies patients with high-intermediate risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. <i>Cancer</i> , 2019, 125, 398-405.	4.1	35
13	Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution. <i>Gynecologic Oncology</i> , 2019, 152, 1-2.	1.4	0
14	<i>STAT3/PIAS3</i> Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. <i>Cancer Research</i> , 2018, 78, 1739-1750.	0.9	18
15	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. <i>Journal of the National Cancer Institute</i> , 2018, 110, 517-526.	6.3	9
16	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 806.	7.1	136
17	The <i>FOXA2</i> transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. <i>Cancer</i> , 2018, 124, 65-73.	4.1	27
18	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 174-180.	1.4	83

#	ARTICLE	IF	CITATIONS
19	Endometrial cancer: Molecular markers and management of advanced stage disease. <i>Gynecologic Oncology</i> , 2018, 150, 569-580.	1.4	133
20	Functional characterization of recurrent <i>FOXA2</i> mutations seen in endometrial cancers. <i>International Journal of Cancer</i> , 2018, 143, 2955-2961.	5.1	6
21	Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. <i>Oncogene</i> , 2017, 36, 168-181.	5.9	99
22	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. <i>Cancer</i> , 2017, 123, 3261-3268.	4.1	72
23	Traditional Approaches to Molecular Genetic Analysis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 99-118.	1.6	2
24	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 366-373.	1.4	40
25	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 464.	7.1	510
26	Primum non nocere : Are we ready for POLE testing in endometrial cancer?. <i>Gynecologic Oncology</i> , 2017, 147, 240-242.	1.4	7
27	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
28	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	1.4	77
29	Identification of endometrial cancer methylation features using combined methylation analysis methods. <i>PLoS ONE</i> , 2017, 12, e0173242.	2.5	18
30	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	1.8	23
31	Novel <i>SOX17</i> frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. <i>Oncotarget</i> , 2017, 8, 68758-68768.	1.8	15
32	The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role. <i>Gynecologic Oncology</i> , 2016, 143, 398-405.	1.4	12
33	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.	2.5	6
34	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3062-3068.	1.6	141
35	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. <i>Gastroenterology</i> , 2016, 151, 440-447.e1.	1.3	36
36	Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. <i>Nucleic Acids Research</i> , 2016, 44, 4105-4122.	14.5	38

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 933-938.	2.5	38
38	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 312-317.	1.4	75
39	The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016, 140, 264-269.	1.4	22
40	Novel APC promoter and exon 1B deletion and allelic silencing in three mutation-negative classic familial adenomatous polyposis families. <i>Genome Medicine</i> , 2015, 7, 42.	8.2	19
41	Patterns of <i>CTCF</i> and <i>ZFX3</i> Mutation and Associated Outcomes in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv249.	6.3	37
42	Noncatalytic <i>PTEN</i> missense mutation predisposes to organ-selective cancer development in vivo. <i>Genes and Development</i> , 2015, 29, 1707-1720.	5.9	29
43	Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 614-619.	1.4	9
44	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4301-4308.	1.6	163
45	Polymerase É (<i>POLE</i>) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. <i>Cancer</i> , 2015, 121, 386-394.	4.1	142
46	Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model. <i>F1000Research</i> , 2015, 4, 214.	1.6	125
47	<i>PIK3CA</i> mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3550-3550.	1.6	4
48	Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. <i>BMC Genomics</i> , 2014, 15, 868.	2.8	49
49	A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 38-43.	1.4	82
50	High Frequency Strand Slippage Mutations in <i>CTCF</i> in MSI-Positive Endometrial Cancers. <i>Human Mutation</i> , 2014, 35, 63-65.	2.5	28
51	Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor. <i>Gynecologic Oncology</i> , 2014, 135, 133-141.	1.4	20
52	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. <i>Modern Pathology</i> , 2014, 27, 128-134.	5.5	218
53	Hypermethylation of miR-203 in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2014, 133, 340-345.	1.4	49
54	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	2.8	145

#	ARTICLE	IF	CITATIONS
55	Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. <i>Gynecologic Oncology</i> , 2014, 133, 43-47.	1.4	35
56	Frequent mutations in the RPL22 gene and its clinical and functional implications. <i>Gynecologic Oncology</i> , 2013, 128, 470-474.	1.4	58
57	<i>BRCA1</i> , <i>TP53</i> , and <i>CHEK2</i> germline mutations in uterine serous carcinoma. <i>Cancer</i> , 2013, 119, 332-338.	4.1	99
58	Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. <i>Cancer Letters</i> , 2013, 335, 314-322.	7.2	8
59	CMS: A Web-Based System for Visualization and Analysis of Genome-Wide Methylation Data of Human Cancers. <i>PLoS ONE</i> , 2013, 8, e60980.	2.5	36
60	Glycogen Synthase Kinase 3 β Inhibition as a Therapeutic Approach in the Treatment of Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16617-16637.	4.1	18
61	Promoter Hypomethylation of EpCAM-Regulated <i>Bone Morphogenetic Protein</i> Gene Family in Recurrent Endometrial Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6272-6285.	7.0	37
62	Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies. <i>Cancer Prevention Research</i> , 2012, 5, 435-443.	1.5	18
63	Reduced DICER1 Elicits an Interferon Response in Endometrial Cancer Cells. <i>Molecular Cancer Research</i> , 2012, 10, 316-325.	3.4	15
64	ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 357-366.	2.8	179
65	Use of mutation profiles to refine the classification of endometrial carcinomas. <i>Journal of Pathology</i> , 2012, 228, 20-30.	4.5	261
66	Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2012, 124, 31-35.	1.4	169
67	Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?. <i>Gynecologic Oncology</i> , 2012, 124, 340-346.	1.4	30
68	FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features. <i>PLoS ONE</i> , 2012, 7, e30801.	2.5	150
69	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	21.4	279
70	Lower Uterine Segment Involvement is Associated with Poor Outcomes in Early-Stage Endometrioid Endometrial Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 1419-1424.	1.5	26
71	<i>DICER1</i> expression and outcomes in endometrioid endometrial adenocarcinoma. <i>Cancer</i> , 2011, 117, 1446-1453.	4.1	26
72	Aberrant Methylation of the X-Linked Ribosomal S6 Kinase <i>RPS6KA6 (RSK4)</i> in Endometrial Cancers. <i>Clinical Cancer Research</i> , 2011, 17, 2120-2129.	7.0	39

#	ARTICLE	IF	CITATIONS
73	Identification of a Novel <i>TP53</i> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1568.	7.4	146
74	FGFR2 mutations are rare across histologic subtypes of ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 125-129.	1.4	45
75	Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2010, 117, 239-247.	1.4	37
76	Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. <i>Gynecologic Oncology</i> , 2010, 119, 146-150.	1.4	9
77	The MLH1 α^{93} promoter variant influences gene expression. <i>Cancer Epidemiology</i> , 2010, 34, 93-95.	1.9	16
78	Genome remodelling in a basal-like breast cancer metastasis and xenograft. <i>Nature</i> , 2010, 464, 999-1005.	27.8	1,077
79	Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. <i>Nucleic Acids Research</i> , 2009, 37, 4603-4612.	14.5	70
80	<i>ATR</i> Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2009, 27, 3091-3096.	1.6	71
81	Epigenetic Repression of <i>microRNA-129-2</i> Leads to Overexpression of <i>SOX4</i> Oncogene in Endometrial Cancer. <i>Cancer Research</i> , 2009, 69, 9038-9046.	0.9	262
82	Absence of MGMT promoter methylation in endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 112, 224-228.	1.4	19
83	Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. <i>Familial Cancer</i> , 2009, 8, 501-504.	1.9	16
84	<i>DICER1</i> Mutations in Familial Pleuropulmonary Blastoma. <i>Science</i> , 2009, 325, 965-965.	12.6	588
85	Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair. <i>Gynecologic Oncology</i> , 2008, 108, 438-444.	1.4	4
86	Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation. <i>Cancer Research</i> , 2008, 68, 6902-6907.	0.9	134
87	Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers. <i>Clinical Cancer Research</i> , 2007, 13, 2882-2889.	7.0	34
88	Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type. <i>Journal of Clinical Oncology</i> , 2007, 25, 2042-2048.	1.6	186
89	Evidence for heritable predisposition to epigenetic silencing of MLH1. <i>International Journal of Cancer</i> , 2007, 120, 1684-1688.	5.1	75
90	Body mass index: Relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 104, 535-539.	1.4	54

#	ARTICLE	IF	CITATIONS
91	Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. <i>Gynecologic Oncology</i> , 2007, 105, 390-394.	1.4	16
92	DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5104-5111.	7.0	34
93	DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. <i>Modern Pathology</i> , 2006, 19, 1333-1338.	5.5	58
94	Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. <i>Gynecologic Oncology</i> , 2006, 100, 107-110.	1.4	18
95	Transcriptional profiling endometrial carcinomas microdissected from DES-treated mice identifies changes in gene expression associated with estrogenic tumor promotion. <i>International Journal of Cancer</i> , 2006, 119, 1843-1849.	5.1	10
96	MLH3 Mutation in Endometrial Cancer. <i>Cancer Research</i> , 2006, 66, 7502-7508.	0.9	25
97	IGSF4 promoter methylation and expression silencing in human cervical cancer. <i>Gynecologic Oncology</i> , 2005, 96, 150-158.	1.4	37
98	Diethylstilbestrol effects and lymphomagenesis in Mlh1 α -deficient mice. <i>International Journal of Cancer</i> , 2005, 115, 666-669.	5.1	10
99	Low Allele Frequency of MLH1 D132H in American Colorectal and Endometrial Cancer Patients. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1723-1727.	1.3	14
100	A Drosophila Model of Multiple Endocrine Neoplasia Type 2. <i>Genetics</i> , 2005, 171, 1057-1081.	2.9	82
101	A Human Yeast Artificial Chromosome Containing the Multiple Endocrine Neoplasia Type 2B Ret Mutation Does Not Induce Medullary Thyroid Carcinoma but Does Support the Growth of Kidneys and Partially Rescues Enteric Nervous System Development in Ret-Deficient Mice. <i>American Journal of Pathology</i> , 2005, 166, 265-274.	3.8	8
102	Increased Risk for Hereditary Nonpolyposis Colorectal Cancer-Associated Synchronous and Metachronous Malignancies in Patients with Microsatellite Instability-Positive Endometrial Carcinoma Lacking MLH1 Promoter Methylation. <i>Clinical Cancer Research</i> , 2004, 10, 481-490.	7.0	45
103	RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 935-939.	1.3	32
104	Expression mapping at 12p12-13 in advanced prostate carcinoma. <i>International Journal of Cancer</i> , 2004, 109, 668-672.	5.1	21
105	Penetrance and Expressivity of MSH6 Germline Mutations in Seven Kindreds Not Ascertained by Family History. <i>American Journal of Human Genetics</i> , 2004, 74, 1262-1269.	6.2	61
106	Expression Profiling of Mouse Endometrial Cancers Microdissected from Ethanol-Fixed, Paraffin-Embedded Tissues. <i>American Journal of Pathology</i> , 2003, 162, 755-762.	3.8	32
107	Human telomerase RNA mutations and bone marrow failure. <i>Lancet</i> , The, 2003, 361, 1993-1994.	13.7	22
108	Antisense transcripts at the EMX2 locus in human and mouse α - β . Sequence data from this article have been deposited with the GenBank Data Library under Accession Nos. AY117034, AY117413, AY117414, and AY117415.. <i>Genomics</i> , 2003, 81, 58-66.	2.9	41

#	ARTICLE	IF	CITATIONS
109	Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5908-5913.	7.1	216
110	CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Research, 2003, 63, 2033-6.	0.9	76
111	Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clinical Cancer Research, 2003, 9, 2277-87.	7.0	81
112	MSI in endometrial carcinoma: Absence of MLH1 promoter methylation is associated with increased familial risk for cancers. International Journal of Cancer, 2002, 99, 697-704.	5.1	40
113	Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clinical Cancer Research, 2002, 8, 1849-56.	7.0	31
114	Characterization of the Homeodomain Gene EMX2: Sequence Conservation, Expression Analysis, and a Search for Mutations in Endometrial Cancers. Genomics, 2001, 76, 37-44.	2.9	33
115	Methylation and mutational analysis of p27 ^{kip1} in prostate carcinoma. Prostate, 2001, 48, 248-253.	2.3	35
116	Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. Genes Chromosomes and Cancer, 2001, 32, 295-301.	2.8	18
117	No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. Human Mutation, 2001, 17, 117-121.	2.5	4
118	The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia. Nature Genetics, 2001, 29, 179-183.	21.4	245
119	Clinical significance of microsatellite instability in endometrial carcinoma. Cancer, 2000, 89, 1758-1764.	4.1	117
120	Absence of PTEN Repeat Tract Mutation in Endometrial Cancers with Microsatellite Instability. Gynecologic Oncology, 2000, 79, 101-106.	1.4	27
121	16q loss of heterozygosity and microsatellite instability in Wilms' tumor. Journal of Pediatric Surgery, 2000, 35, 891-897.	1.6	22
122	Atypical Clustering of Gynecologic Malignancies: A Family Study Including Molecular Analysis of Candidate Genes. Gynecologic Oncology, 2000, 77, 18-25.	1.4	8
123	Mutational Analysis of the PMS2 Gene in Sporadic Endometrial Cancers with Microsatellite Instability. Gynecologic Oncology, 1999, 74, 395-399.	1.4	16
124	Germline mutations in the multiple endocrine neoplasia type 1 gene: Evidence for frequent splicing defects. Human Mutation, 1999, 13, 175-185.	2.5	73
125	A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Molecular Carcinogenesis, 1999, 24, 90-98.	2.7	66
126	Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. , 1999, 85, 119-126.		44

#	ARTICLE	IF	CITATIONS
127	A 1-Mb Bacterial Clone Contig Spanning the Endometrial Cancer Deletion Region at 1p32â€“p33. <i>Genomics</i> , 1999, 57, 62-69.	2.9	12
128	Germline mutations in the multiple endocrine neoplasia type 1 gene: Evidence for frequent splicing defects. <i>Human Mutation</i> , 1999, 13, 175.	2.5	5
129	PTEN Mutations in Endometrial Cancers with 10q LOH: Additional Evidence for the Involvement of Multiple Tumor Suppressors. <i>Gynecologic Oncology</i> , 1998, 71, 391-395.	1.4	53
130	Four new mutations in the DNA mismatch repair gene MLH1 in colorectal cancers with microsatellite instability. <i>Human Mutation</i> , 1998, 12, 73-73.	2.5	3
131	Mapping an Endometrial Cancer Tumor Suppressor Gene at 10q25 and Development of a Bacterial Clone Contig for the Consensus Deletion Interval. <i>Genomics</i> , 1998, 52, 9-16.	2.9	24
132	Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. <i>Oncogene</i> , 1997, 14, 3103-3106.	5.9	48
133	Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability. <i>Genes Chromosomes and Cancer</i> , 1997, 18, 42-49.	2.8	47
134	Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. <i>Genes Chromosomes and Cancer</i> , 1997, 18, 219-227.	2.8	98
135	Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. <i>Genes Chromosomes and Cancer</i> , 1997, 19, 43-51.	2.8	58
136	Loss of Heterozygosity of Chromosome 3p Sequences Is an Infrequent Event in Endometrial Cancer. <i>Gynecologic Oncology</i> , 1996, 60, 308-312.	1.4	5
137	Dinucleotide Repeat in the third Intron of the Fabp3lmdgi Putative Tumor Suppressor Gene. <i>Disease Markers</i> , 1996, 13, 57-59.	1.3	5
138	Infrequent CDKN2 mutation in human differentiated thyroid cancers. , 1996, 15, 5-10.		24
139	Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. <i>Human Molecular Genetics</i> , 1996, 5, 1017-1021.	2.9	20
140	Reduced Survival in Patients With Ductal Pancreatic Adenocarcinoma Associated With CDKN2 Mutation. <i>Journal of the National Cancer Institute</i> , 1996, 88, 680-682.	6.3	34
141	Low frequency of CDKN2 mutation in endometrial carcinomas. <i>Molecular Carcinogenesis</i> , 1995, 13, 210-212.	2.7	19
142	Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 189-195.	2.8	77
143	A Familial Syndrome of Pancreatic Cancer and Melanoma with a Mutation in the CDKN2 Tumor-Suppressor Gene. <i>New England Journal of Medicine</i> , 1995, 333, 975-977.	27.0	283
144	Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. <i>Human Molecular Genetics</i> , 1995, 4, 1987-1988.	2.9	41

#	ARTICLE	IF	CITATIONS
145	Linkage analysis of X-linked cleft palate and ankyloglossia in Manitoba Mennonite and British Columbia Native kindreds. <i>Human Genetics</i> , 1994, 94, 141-8.	3.8	21
146	Inherited cancers associated with the RET proto-oncogene. <i>Current Opinion in Genetics and Development</i> , 1994, 4, 446-452.	3.3	22
147	A new polymorphic marker (D10S97) tightly linked to the multiple endocrine neoplasia type 2A (MEN2A) locus. <i>Human Genetics</i> , 1993, 90, 516-20.	3.8	1
148	A new HLA-DRB1 allele formed by an intra-exonic interallelic crossover. <i>Tissue Antigens</i> , 1993, 42, 141-143.	1.0	12
149	Physical and Genetic Maps for Chromosome 10. <i>Genomics</i> , 1993, 16, 320-324.	2.9	13
150	Genomic and Yeast Artificial Chromosome Long-Range Regular Article Linking Six Loci in 10q11.2 and Spanning the Multiple Endocrine Neoplasia Type 2A (MEN2A) Region. <i>Genomics</i> , 1993, 17, 611-617.	2.9	10
151	Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. <i>Human Molecular Genetics</i> , 1993, 2, 851-856.	2.9	1,223
152	The genomic organisation of the human pseudoautosomal gene MIC2 and the detection of a related locus. <i>Human Molecular Genetics</i> , 1993, 2, 417-422.	2.9	47
153	Human repeat element-mediated PCR: Cloning and mapping of chromosome 10 DNA markers. <i>Genomics</i> , 1992, 13, 409-414.	2.9	10
154	A high-resolution meiotic mapping panel for the pericentromeric region of chromosome 10. <i>Genomics</i> , 1992, 13, 607-612.	2.9	12
155	A cluster of CpG islands at D10S94, near the locus responsible for multiple endocrine neoplasia type 2A (MEN2A). <i>Genomics</i> , 1992, 13, 339-343.	2.9	14
156	Identification and characterization of a gene at D10S94 in the MEN2A region. <i>Genomics</i> , 1992, 13, 344-348.	2.9	16
157	Regional assignment of the human uroporphyrinogen III synthase (UROS) gene to chromosome 10q25.2?q26.3. <i>Human Genetics</i> , 1991, 87, 18-22.	3.8	56
158	Rapid cloning and characterization of new chromosome 10 DNA markers by Alu element-mediated PCR. <i>Genomics</i> , 1990, 7, 614-620.	2.9	74
159	The α subunit locus of the human fibronectin receptor: DNA restriction fragment length polymorphism and linkage mapping studies. <i>Human Genetics</i> , 1989, 83, 383-390.	3.8	28
160	The pseudoautosomal boundary in man is defined by an Alu repeat sequence inserted on the Y chromosome. <i>Nature</i> , 1989, 337, 81-84.	27.8	120
161	Evolutionary conservation of the human homologue of the yeast cell cycle control gene cdc2 and assignment of Cd2 to chromosome 10. <i>Human Genetics</i> , 1988, 78, 333-337.	3.8	24
162	Linkage analysis of multiple endocrine neoplasia type 2A (MEN-2A) and three DNA markers on chromosome 20: Evidence against synteny. <i>Cancer Genetics and Cytogenetics</i> , 1987, 27, 327-334.	1.0	11

#	ARTICLE	IF	CITATIONS
163	Mapping the limits of the human pseudoautosomal region and a candidate sequence for the male-determining gene. <i>Nature</i> , 1987, 328, 273-275.	27.8	56